NCT00395629 - Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

March 31, 2009

Conditions

Iron OverloadHereditary Hemochromatosis

Interventions

DRUG

Deferasirox (ICL670)

Trial Locations (18)

Rochester General Hospital, Rochester

Carolinas Medical Center, Charlotte

Three Medical Park, Columbia

Ohio State University Medical Center, Columbus

Henry Ford Health System, Detroit

Mayo Clinic, Rochester

St. Louis University, St Louis

UC Irvine/Long Beach, Long Beach

University of Connecticut Health Center, Farmington

Novartis Investigative Site, Brisbane

Novartis Investigative Site, London

Novartis Investigative Site, Rennes

Novartis Investigative Site, Chemnitz

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Magdeburg

Novartis Investigative Site, Oberhausen

Novartis Investigative Site, Modena

Novartis Investigative Site, Monza